Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Press releases

October 30, 2017 | REGULATORY

Immunovia receives SEK4.9 Million grant from Swelife Accelerator Innovation Program

Read press release
October 23, 2017 | REGULATORY

Immunovia signs major autoimmune biomarker discovery collaboration with Linköping University

Read press release
October 2, 2017

Immunovia AB on track regarding application for listing on Nasdaq Stockholm’s main market

Read press release
September 26, 2017 | REGULATORY

Management and employees of Immunovia subscribe for new shares by exercising warrants

Read press release
September 7, 2017 | REGULATORY

Immunovia announces collaboration with Lund University Diabetes Centre for the early detection of pancreatic cancer in diabetes risk group

Read press release
August 23, 2017 | REGULATORY

Immunovia Interim report, January-June 2017

Read press release
August 18, 2017

Immunovia invites to a conference call on August 23, 2017

Read press release
July 17, 2017 | REGULATORY

Leading expert on pancreatic cancer, Professor Stephen Pereira at University College London, joins Immunovia’s Scientific Advisory Board

Read press release
June 30, 2017 | REGULATORY

Immunovia together with Oregon Health and Science University awarded one of the Pancreatic Cancer Action Network 2017 Research Grants

Read press release
June 28, 2017 | REGULATORY

Immunovia establishes US headquarters, including CLIA reference laboratory, in Boston

Read press release
June 21, 2017 | REGULATORY

Immunovia’s IMMray™ presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy

Read press release
June 16, 2017 | REGULATORY

Immunovia AB announces timetable for listing on Nasdaq Stockholm’s main market

Read press release
1 20 21 22 23 24 27